Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | BRS3 | P32247 | 8/20 | 0.45 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515660 | 0.84 | NR1H2 (0.52) | ACHEBRS3SLC6A3SLC6A4NR1H2 | |
| SCHEMBL9854183 | 0.84 | ACHE (0.48) | ACHEBRS3SLC6A3SLC6A4NR1H2 | |
| SCHEMBL8875151 | 0.84 | ACHE (0.48) | ACHEBRS3SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL4074654 | 0.83 | ALDH1A1 (0.47) | ACHEBRS3SLC6A3SLC6A4NR1H2 | |
| SCHEMBL489306 | 0.81 | NR1H2 (0.48) | ACHEBRS3SLC6A3SLC6A4NR1H2 | |
| SCHEMBL283 | 0.81 | SLC6A3 (0.48) | ACHEBRS3SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL4080196 | 0.81 | BRS3 (0.47) | ACHEBRS3SLC6A3SLC6A4LTB4R2 | |
| SCHEMBL9569998 | 0.80 | SLC6A3 (0.47) | ACHEBRS3SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3515882 | 0.79 | GPR52 (0.55) | BRS3GPR52LTB4R2LPAR1 | |
| SCHEMBL9447390 | 0.79 | ACHE (0.46) | ACHEBRS3SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | ACHE 3789/4885BRS3 1/4885GPR52 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.